Funding for this research was provided by:
Pfizer Japan (203150600035)
Dainippon Sumitomo Pharma
Olympus
Stella Pharma
Medical Platform Co.
Novartis Pharmaceuticals
Bayer
Cmic Inc
Article History
First Online: 30 April 2018
Compliance with Ethical Standards
:
: Izumi Sato has received support from K-CONNEX and a grant from the Pfizer Health Research Foundation (Grant number 203150600035). Koji Kawakami received research funds from Dainippon Sumitomo Pharma, Olympus, Stella Pharma, Medical Platform Co., Novartis Pharmaceutical K.K., Bayer, and CMIC Inc. He has also received consultation fees from Olympus, Kyowa Hakko Kirin, Kaken Pharmaceutical, and Takeda Pharmaceutica, and lecture fees from Daiichi Sankyo, Eisai, Boehringer Ingelheim Japan Inc., Mitsubishi Tanabe Pharma, Abbie, Chugai, and Sanofi K.K. No other disclosures were reported. Yosuke Yamamoto and Genta Kato have no conflicts of interest that are directly relevant to the content of this study.
: This work was supported by the Pfizer Health Research Foundation (Grant number 203150600035). This financial assistance was used to conduct the study described in the manuscript and to assist with the preparation of the manuscript.
: The Institutional Review Board of Kyoto University approved the study protocol (approval R0541) on April 22, 2016. A collaborative research agreement was obtained from MDV.
: The requirement for written informed consent was waived because this was a retrospective study analyzing anonymized data.
: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.